[
  {
    "nctId": "NCT01",
    "acronym": "NCT01",
    "title": "Study of pembrolizumab instead of CAPOX",
    "phase": "Phase III",
    "recruitment": "Completed",
    "therapies": [
      {
        "id": 1,
        "therapyName": "Capecitabine + Oxaliplatin",
        "synonyms": null
      },
      {
        "id": 2,
        "therapyName": "Pembrolizumab",
        "synonyms": null
      }
    ],
    "ageGroups": [
      "adult",
      "senior"
    ],
    "gender": "both",
    "variantRequirements": "Yes",
    "sponsors": "Hartwig Medical Foundation",
    "updateDate": "12/05/2023",
    "indications": [
      {
        "id": 162,
        "name": "cancer",
        "source": "DOID"
      }
    ],
    "variantRequirementDetails": [
      {
        "molecularProfile": {
          "id": 3,
          "profileName": "MSI high"
        },
        "requirementType": "required"
      }
    ],
    "clinicalTrialLocations": [
      {
        "nctId": "NCT01",
        "facility": "HMF Sequencing Lab",
        "city": "Amsterdam",
        "country": "Netherlands",
        "status": null,
        "state": "NH",
        "zip": "1234 AM",
        "clinicalTrialContacts": [
        ]
      }
    ],
    "coveredCountries": [
    ],
    "trial_references": [
      {
        "id": 10,
        "patient_populations": [
          {
            "id": 20,
            "is_control": true,
            "group_name": "CAPOX",
            "n_patients": "40",
            "n_female": "30",
            "n_male": "10",
            "age_min": "50",
            "age_max": "60",
            "median_age": "55",
            "n_65_or_older": null,
            "n_ecog_0": "3",
            "n_ecog_1": "27",
            "n_ecog_2": "10",
            "n_ecog_3": null,
            "n_ecog_4": null,
            "n_ecog_0_to_1": null,
            "n_ecog_1_to_2": null,
            "highest_ecog_score": 2,
            "n_localization_primary_tumor": null,
            "other_mutations": "EGFR Staining None: 0 (0%), Weak 1+: 40 (100.0%)",
            "n_primary_tumor_removed_complete": null,
            "n_primary_tumor_removed_partial": null,
            "n_primary_tumor_removed": null,
            "n_previous_lines_of_therapy_1": "40",
            "n_previous_lines_of_therapy_2": null,
            "n_previous_lines_of_therapy_3": null,
            "n_previous_lines_of_therapy_4_or_more": null,
            "n_prior_systemic_therapy": null,
            "n_stage_description": null,
            "n_mutation_status": null,
            "n_high_microsatellite_instability": null,
            "median_follow_up_for_survival": null,
            "median_follow_up_for_progression_free_survival": null,
            "median_follow_up_randomization_to_data_cut_off": null,
            "metastatic_sites": "Liver: 20 (50.0%), Lung: 10 (25.0%)",
            "time_of_metastases": "Both",
            "therapy": {
              "id": 1,
              "therapyName": "Capecitabine + Oxaliplatin",
              "synonyms": null,
              "therapyDescriptions": [
                {
                  "description": "Description of CAPOX",
                  "references": [
                    {
                      "id": 92,
                      "pubMedId": 12345678,
                      "title": "In a phase3 trial, pembrolizumab seems better than CAPOX",
                      "url": "http://www.ncbi.nlm.nih.gov/pubmed/12345678"
                    }
                  ]
                }
              ],
              "createDate": "01/01/2001",
              "updateDate": "02/02/2002"
            },
            "analysis_groups": [
              {
                "id": 30,
                "name": "CAPOX",
                "outcome": "N/A",
                "n_patients": "40",
                "end_point_metrics": [
                  {
                    "id": 40,
                    "trial_analysis_group_id": 30,
                    "end_point": {
                      "id": 50,
                      "name": "Disease Control Rate",
                      "definition": "the proportion of patients who have achieved complete response, partial response, and stable disease",
                      "unit_of_measure": "Percent"
                    },
                    "end_point_type": "NA",
                    "value": "50.0",
                    "confidence_interval_95": null,
                    "numerator": "20",
                    "denominator": "40",
                    "derived_metrics": [
                    ]
                  },
                  {
                    "id": 41,
                    "trial_analysis_group_id": 30,
                    "end_point": {
                      "id": 51,
                      "name": "Objective/Overall Response Rate",
                      "definition": "the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period",
                      "unit_of_measure": "Percent"
                    },
                    "end_point_type": "NA",
                    "value": "25.0",
                    "confidence_interval_95": null,
                    "numerator": "10",
                    "denominator": "40",
                    "derived_metrics": [
                    ]
                  }
                ],
                "notes": null
              }
            ],
            "efficacy_evidence": [
            ],
            "therapy_details": null,
            "prior_therapies": "Chemo, radiation",
            "race": "Asian: 16,\nWhite: 24",
            "region": "",
            "notes": null
          },
          {
            "id": 21,
            "is_control": false,
            "group_name": "Pembrolizumab",
            "n_patients": "40",
            "n_female": "21",
            "n_male": "19",
            "age_min": "48",
            "age_max": "84",
            "median_age": "64",
            "n_65_or_older": null,
            "n_ecog_0": null,
            "n_ecog_1": "37",
            "n_ecog_2": "3",
            "n_ecog_3": null,
            "n_ecog_4": null,
            "n_ecog_0_to_1": null,
            "n_ecog_1_to_2": null,
            "highest_ecog_score": 2,
            "n_localization_primary_tumor": null,
            "other_mutations": "EGFR Staining None: 2 (5.0%), Weak 1+: 38 (95.0%)",
            "n_primary_tumor_removed_complete": null,
            "n_primary_tumor_removed_partial": null,
            "n_primary_tumor_removed": null,
            "n_previous_lines_of_therapy_1": "40",
            "n_previous_lines_of_therapy_2": null,
            "n_previous_lines_of_therapy_3": null,
            "n_previous_lines_of_therapy_4_or_more": null,
            "n_prior_systemic_therapy": null,
            "n_stage_description": null,
            "n_mutation_status": null,
            "n_high_microsatellite_instability": null,
            "median_follow_up_for_survival": null,
            "median_follow_up_for_progression_free_survival": null,
            "median_follow_up_randomization_to_data_cut_off": null,
            "metastatic_sites": "Liver: 30 (75.0%), Lung: 10 (25.0%)",
            "time_of_metastases": null,
            "therapy": {
              "id": 2,
              "therapyName": "Pembrolizumab",
              "synonyms": null,
              "therapyDescriptions": [
                {
                  "description": "Description of pembrolizumab",
                  "references": [
                    {
                      "id": 92,
                      "pubMedId": 12345678,
                      "title": "In a phase3 trial, pembrolizumab seems better than CAPOX",
                      "url": "http://www.ncbi.nlm.nih.gov/pubmed/12345678"
                    }
                  ]
                }
              ],
              "createDate": "01/01/2001",
              "updateDate": "02/02/2002"
            },
            "analysis_groups": [
              {
                "id": 31,
                "name": "Pembrolizumab",
                "outcome": "Positive",
                "n_patients": "40",
                "end_point_metrics": [
                  {
                    "id": 42,
                    "trial_analysis_group_id": 31,
                    "end_point": {
                      "id": 50,
                      "name": "Disease Control Rate",
                      "definition": "the proportion of patients who have achieved complete response, partial response, and stable disease",
                      "unit_of_measure": "Percent"
                    },
                    "end_point_type": "SECONDARY",
                    "value": "75.0",
                    "confidence_interval_95": null,
                    "numerator": "30",
                    "denominator": "40",
                    "derived_metrics": [
                      {
                        "relative_metric_id": 60,
                        "comparator_statistic": null,
                        "comparator_statistic_type": null,
                        "confidence_interval95_cs": null,
                        "p_value": "<0.0001"
                      }
                    ]
                  },
                  {
                    "id": 43,
                    "trial_analysis_group_id": 31,
                    "end_point": {
                      "id": 51,
                      "name": "Objective/Overall Response Rate",
                      "definition": "the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period",
                      "unit_of_measure": "Percent"
                    },
                    "end_point_type": "SECONDARY",
                    "value": "50.0",
                    "confidence_interval_95": "40.0-60.0",
                    "numerator": "20",
                    "denominator": "40",
                    "derived_metrics": [
                      {
                        "relative_metric_id": 61,
                        "comparator_statistic": null,
                        "comparator_statistic_type": null,
                        "confidence_interval95_cs": null,
                        "p_value": "<0.0001"
                      }
                    ]
                  }
                ],
                "notes": null
              }
            ],
            "efficacy_evidence": [
              {
                "id": 70,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a phase3 trial, pembrolizumab seems better than CAPOX",
                "molecularProfile": {
                  "id": 3,
                  "profileName": "MSI high"
                },
                "therapy": {
                  "id": 1,
                  "therapyName": "Treatment 1",
                  "synonyms": null
                },
                "indication": {
                  "id": 162,
                  "name": "cancer",
                  "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                  {
                    "id": 92,
                    "pubMedId": 12345678,
                    "title": "In a phase3 trial, pembrolizumab seems better than CAPOX",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12345678"
                  }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "referencedMetrics": [
                  {
                    "id": 90,
                    "trial_analysis_group_id": 31,
                    "end_point": {
                      "id": 91,
                      "name": "Median Overall Survival",
                      "definition": "the time from randomization until death from any cause",
                      "unit_of_measure": "Months"
                    },
                    "end_point_type": "PRIMARY",
                    "value": "4.3",
                    "confidence_interval_95": "4.2-4.4",
                    "numerator": null,
                    "denominator": null,
                    "derived_metrics": [
                    ]
                  }
                ]
              }
            ],
            "therapy_details": null,
            "prior_therapies": "Chemo",
            "race": "Asian: 10,\nWhite: 30",
            "region": "",
            "notes": null
          }
        ],
        "reference": {
          "id": 92,
          "pubMedId": 12345678,
          "title": "In a phase3 trial, pembrolizumab seems better than CAPOX",
          "url": "http://www.ncbi.nlm.nih.gov/pubmed/12345678"
        }
      }
    ],
    "other_trial_registration_numbers": null,
    "masking": "None (Open Label)",
    "allocation": "randomized",
    "cancer_stage": "metastatic",
    "disease_assessment": "Measurable",
    "disease_assessment_criteria": "RECIST",
    "therapeutic_setting": null
  }
]
